Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 27, 2018

Wearable Inertial Sensor Technology Produces Endpoints with Good Reliability in Healthy Volunteers and Can Detect Changes in Parkinson Disease Patients with Levodopa (P6.086)

Vesper Ramos, Melissa Naylor, Charmaine Demanuele, Hao Zhang, Stephen Amato, Farhan Hameed, Paul Wacnik, Tairmae Kangaroo, Vibha Anand, Erhan Bilal, Bryan Ho, Peter Bergethon, Michael Kelley Erb, Daniel Karlin
First published April 9, 2018,
Vesper Ramos
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Naylor
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charmaine Demanuele
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Zhang
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Amato
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farhan Hameed
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Wacnik
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tairmae Kangaroo
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibha Anand
2IBM T.J. Watson Research Center, Yorktown, NY, and Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erhan Bilal
2IBM T.J. Watson Research Center, Yorktown, NY, and Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Ho
3Tufts Medical Center Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bergethon
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kelley Erb
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Karlin
1Pfizer Inc., Early Clinical Development, Worldwide Research and Development, Cambridge, MA Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Wearable Inertial Sensor Technology Produces Endpoints with Good Reliability in Healthy Volunteers and Can Detect Changes in Parkinson Disease Patients with Levodopa (P6.086)
Vesper Ramos, Melissa Naylor, Charmaine Demanuele, Hao Zhang, Stephen Amato, Farhan Hameed, Paul Wacnik, Tairmae Kangaroo, Vibha Anand, Erhan Bilal, Bryan Ho, Peter Bergethon, Michael Kelley Erb, Daniel Karlin
Neurology Apr 2018, 90 (15 Supplement) P6.086;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the performance of wearable inertial sensor technology in quantifying Parkinson Disease (PD) signs

Background: Objective monitoring of Parkinson Disease (PD) signs is important to adequately assess response to treatments. Currently, PD treatments are adjudicated based on expert clinical rating scales and patient diaries, which are often insensitive, episodic and subjective with inherent rater bias. Wearable inertial sensor technology, such as the Mobility Lab system (www.apdm.com) can quantify gait metrics, and have been studied to monitor PD signs.

Design/Methods: We compared endpoints of the Mobility Lab 2-minute walk test in 41 healthy volunteers (HV) and in 25 PD patients. HV have two test sessions at least 1 hour apart. Each PD patient also performed the task twice: one in ON state (~1 hour after scheduled levodopa dose) and again in OFF state (immediately prior to next scheduled levodopa dose). PD patients were randomized with half performing ON state evaluations first, and vice versa. Each subject walked 10 meters back and forth for two minutes while wearing sensors at each limb, sternum and lumbar regions.

Results: We found the highest reliability of the following endpoints in HV: cadence (Pearson’s r =0.9860), stride length (r=0.963), and arm range of motion (r=0.962). In PD patients, Mobility Lab endpoints including turn duration (p=0.003), gait speed (p = 0.009), stride length (p = 0.006) and arm range of motion (p = 0.02) significantly differed before and after levodopa intake, and correlated with the Unified Parkinson Disease Rating Scale Motor Score (e.g. turn duration r= 0.4).

Conclusions: The Mobility Lab System 2-minute walk test generated endpoints with good reliability and detected changes in PD patients before and after levodopa. Wearable inertial sensor technology has potential to enhance our ability to detect signals of effectiveness in therapeutics development.

Study Supported by: Pfizer, Inc. and IBM

Disclosure: Dr. Ramos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Naylor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Demanuele has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. & Biogen, Inc. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Hameed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Wacnik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, inc. Dr. Kangaroo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, inc. Dr. Anand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IBM. Dr. Bilal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IBM. Dr. Ho has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Bergethon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer and Biogen. Dr. Erb has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Karlin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise